ARCUS BIOSCIENCES INC (RCUS) Fundamental Analysis & Valuation

NYSE:RCUS • US03969F1093

22.68 USD
+0.25 (+1.11%)
At close: Mar 4, 2026
22.68 USD
0 (0%)
After Hours: 3/4/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RCUS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, RCUS scores 2 out of 10 in our fundamental rating. RCUS was compared to 520 industry peers in the Biotechnology industry. RCUS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, RCUS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. RCUS Profitability Analysis

1.1 Basic Checks

  • RCUS had negative earnings in the past year.
  • In the past year RCUS has reported a negative cash flow from operations.
  • In the past 5 years RCUS reported 4 times negative net income.
  • In the past 5 years RCUS reported 4 times negative operating cash flow.
RCUS Yearly Net Income VS EBIT VS OCF VS FCFRCUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M

1.2 Ratios

  • RCUS has a Return On Assets of -30.99%. This is in the better half of the industry: RCUS outperforms 65.58% of its industry peers.
  • RCUS's Return On Equity of -55.94% is fine compared to the rest of the industry. RCUS outperforms 63.27% of its industry peers.
Industry RankSector Rank
ROA -30.99%
ROE -55.94%
ROIC N/A
ROA(3y)-27.88%
ROA(5y)-20.03%
ROE(3y)-60.25%
ROE(5y)-43.02%
ROIC(3y)N/A
ROIC(5y)N/A
RCUS Yearly ROA, ROE, ROICRCUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60

1.3 Margins

  • RCUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCUS Yearly Profit, Operating, Gross MarginsRCUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. RCUS Health Analysis

2.1 Basic Checks

  • RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RCUS has been increased compared to 1 year ago.
  • Compared to 5 years ago, RCUS has more shares outstanding
  • Compared to 1 year ago, RCUS has a worse debt to assets ratio.
RCUS Yearly Shares OutstandingRCUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
RCUS Yearly Total Debt VS Total AssetsRCUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.41, we must say that RCUS is in the distress zone and has some risk of bankruptcy.
  • RCUS's Altman-Z score of 1.41 is fine compared to the rest of the industry. RCUS outperforms 63.85% of its industry peers.
  • A Debt/Equity ratio of 0.16 indicates that RCUS is not too dependend on debt financing.
  • The Debt to Equity ratio of RCUS (0.16) is worse than 64.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 1.41
ROIC/WACCN/A
WACC8.67%
RCUS Yearly LT Debt VS Equity VS FCFRCUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 4.36 indicates that RCUS has no problem at all paying its short term obligations.
  • RCUS has a Current ratio (4.36) which is comparable to the rest of the industry.
  • A Quick Ratio of 4.36 indicates that RCUS has no problem at all paying its short term obligations.
  • RCUS has a Quick ratio of 4.36. This is comparable to the rest of the industry: RCUS outperforms 52.12% of its industry peers.
Industry RankSector Rank
Current Ratio 4.36
Quick Ratio 4.36
RCUS Yearly Current Assets VS Current LiabilitesRCUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RCUS Growth Analysis

3.1 Past

  • The earnings per share for RCUS have decreased by -6.45% in the last year.
  • The Revenue has decreased by -4.26% in the past year.
  • Measured over the past years, RCUS shows a very strong growth in Revenue. The Revenue has been growing by 26.09% on average per year.
EPS 1Y (TTM)-6.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.59%
Revenue 1Y (TTM)-4.26%
Revenue growth 3Y30.16%
Revenue growth 5Y26.09%
Sales Q2Q%26.92%

3.2 Future

  • Based on estimates for the next years, RCUS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.21% on average per year.
  • The Revenue is expected to grow by 31.68% on average over the next years. This is a very strong growth
EPS Next Y-28.5%
EPS Next 2Y-1.64%
EPS Next 3Y7.86%
EPS Next 5Y17.21%
Revenue Next Year-60.51%
Revenue Next 2Y-21.18%
Revenue Next 3Y-2.78%
Revenue Next 5Y31.68%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RCUS Yearly Revenue VS EstimatesRCUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
RCUS Yearly EPS VS EstimatesRCUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. RCUS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RCUS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCUS Price Earnings VS Forward Price EarningsRCUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCUS Per share dataRCUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.64%
EPS Next 3Y7.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RCUS Dividend Analysis

5.1 Amount

  • No dividends for RCUS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RCUS Fundamentals: All Metrics, Ratios and Statistics

ARCUS BIOSCIENCES INC

NYSE:RCUS (3/4/2026, 8:04:00 PM)

After market: 22.68 0 (0%)

22.68

+0.25 (+1.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners59.66%
Inst Owner Change14.55%
Ins Owners4.49%
Ins Owner Change0.09%
Market Cap2.84B
Revenue(TTM)247.00M
Net Income(TTM)-353.00M
Analysts81.11
Price Target32.95 (45.28%)
Short Float %10.23%
Short Ratio6.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.96%
Min EPS beat(2)4.95%
Max EPS beat(2)14.97%
EPS beat(4)3
Avg EPS beat(4)27.88%
Min EPS beat(4)-8.41%
Max EPS beat(4)100%
EPS beat(8)7
Avg EPS beat(8)30.27%
EPS beat(12)10
Avg EPS beat(12)22.71%
EPS beat(16)13
Avg EPS beat(16)18.49%
Revenue beat(2)1
Avg Revenue beat(2)4.86%
Min Revenue beat(2)-9.4%
Max Revenue beat(2)19.11%
Revenue beat(4)2
Avg Revenue beat(4)95.53%
Min Revenue beat(4)-24.87%
Max Revenue beat(4)397.27%
Revenue beat(8)5
Avg Revenue beat(8)95.59%
Revenue beat(12)7
Avg Revenue beat(12)64.9%
Revenue beat(16)10
Avg Revenue beat(16)53.86%
PT rev (1m)-2.12%
PT rev (3m)-0.2%
EPS NQ rev (1m)-0.33%
EPS NQ rev (3m)10.94%
EPS NY rev (1m)0%
EPS NY rev (3m)5.72%
Revenue NQ rev (1m)-1.53%
Revenue NQ rev (3m)34.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.51
P/FCF N/A
P/OCF N/A
P/B 4.51
P/tB 4.51
EV/EBITDA N/A
EPS(TTM)-3.3
EYN/A
EPS(NY)-4.24
Fwd EYN/A
FCF(TTM)-3.86
FCFYN/A
OCF(TTM)-3.85
OCFYN/A
SpS1.97
BVpS5.03
TBVpS5.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.99%
ROE -55.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.88%
ROA(5y)-20.03%
ROE(3y)-60.25%
ROE(5y)-43.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20%
Cap/Sales 0.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.36
Quick Ratio 4.36
Altman-Z 1.41
F-Score0
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)126.67%
Cap/Depr(5y)233.37%
Cap/Sales(3y)7.88%
Cap/Sales(5y)7.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.59%
EPS Next Y-28.5%
EPS Next 2Y-1.64%
EPS Next 3Y7.86%
EPS Next 5Y17.21%
Revenue 1Y (TTM)-4.26%
Revenue growth 3Y30.16%
Revenue growth 5Y26.09%
Sales Q2Q%26.92%
Revenue Next Year-60.51%
Revenue Next 2Y-21.18%
Revenue Next 3Y-2.78%
Revenue Next 5Y31.68%
EBIT growth 1Y-24.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.44%
EBIT Next 3Y16.06%
EBIT Next 5YN/A
FCF growth 1Y-175%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-183.53%
OCF growth 3YN/A
OCF growth 5YN/A

ARCUS BIOSCIENCES INC / RCUS FAQ

What is the ChartMill fundamental rating of ARCUS BIOSCIENCES INC (RCUS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RCUS.


What is the valuation status for RCUS stock?

ChartMill assigns a valuation rating of 0 / 10 to ARCUS BIOSCIENCES INC (RCUS). This can be considered as Overvalued.


What is the profitability of RCUS stock?

ARCUS BIOSCIENCES INC (RCUS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ARCUS BIOSCIENCES INC?

The Earnings per Share (EPS) of ARCUS BIOSCIENCES INC (RCUS) is expected to decline by -28.5% in the next year.